CTOs on the Move

Cellular Dynamics International, Inc

www.cellulardynamics.com

 
Cellular Dynamics International, Inc. develops and manufactures human cells in the United States of America, Europe, Japan, and internationally. The company’s proprietary iCell Operating System comprises human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs), and custom iPSCs and iCell products (MyCell products). It offers iCell Cardiomyocytes, which are purified human heart cells that beat in a dish and behave just like the heart cells found in the human body for in vitro drug discovery, toxicity testing, and chemical safety, as well as in vivo cellular therapeutics research and development, and stem cell banking; and ...
  • Number of Employees: 0-25
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Medicure

Medicure, Inc. is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aeroflow Healthcare

Live Better Today! Durable medical equipment covered by insurance delivered to your door!

Pulmocide

Pulmocide is a biotechnology company focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.

Commonwealth Biotechnologies

Commonwealth Biotechnologies is a Richmond, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.